Glaucoma Medication Market 2031: Share and Forecast
The Glaucoma Medication Market is expected to register a CAGR of 3.5% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by By Drug Class (Beta Blocker, Prostaglandin Analog, Carbonic Anhydrase Inhibitor, Alpha Adrenergic Agonists, Combination Drugs); Disease (Close Angle Glaucoma, Open Angle Glaucoma)
The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
The report Glaucoma Medication Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Glaucoma Medication Market Segmentation
Drug Class- Beta Blocker
- Prostaglandin Analog
- Carbonic Anhydrase Inhibitor
- Alpha Adrenergic Agonists
- Combination Drugs
- Close Angle Glaucoma
- Open Angle Glaucoma
Strategic Insights
Glaucoma Medication Market Growth Drivers- Aging Population: The main driving factor in the growth of the glaucoma medication market is the aging population across the globe. The incidence of developing glaucoma increases with age. With growing population of the old-aged, the cases of glaucoma increase, thereby resulting in greater demand for medications and innovative treatments to control intraocular pressure and prevent vision loss.
- Increasing Awareness and Early Diagnosis: Advances in the diagnostic technology as well as awareness of glaucoma provide individuals with a better chance at early diagnosis. Because of this, more patients receive treatment before the disease progresses to permanent damage of vision that has resulted in increased demand in the market for effective glaucoma drugs.
- Advancements in drug development: New glaucoma drugs were developed with the help of continuous research and development, employing innovative mechanisms of action, such as Rho kinase inhibitors and sustained-release drug delivery systems. They are associated with better efficacy and lower side effects, and they comply well with patients, which boosts the demand for glaucoma drugs.
- Combination Therapy: A fixed-dose combination therapy is increasingly adopted today as it favors the optimization of compliance and therapy regimens simplification. Two or more active ingredients combined in one formulation reduce the need for multiple eye drops, making glaucoma management easier for the patient, while this also improves therapeutic outcomes.
- Progress in Long-Acting and Implantable Drug Delivery Systems: Newly emerging drug delivery systems, including implants and sustained-release formulations, will be the solutions in achieving treatment adherence. Less frequent dosing results from these technologies and addresses the challenge of non-adherence among glaucoma patients with longer-term control of intraocular pressure.
- Increase in Generic Use: Older glaucoma drugs increasingly enter the market as patents for them expire. The effect on drug prices has been lowering, especially in emerging markets, and improving availability. The increasing generics are improving affordability and increasing patient access to core glaucoma treatments with wider market reach.
- Expansion in Emerging Markets: Asia-Pacific, Latin America, and the Middle East are emerging markets with significant growth opportunities for glaucoma drugs. Entry to healthcare is increasing in these regions; populations are aging; and awareness is growing, demanding more branded and generic glaucoma drugs. This creates a large unserved market.
- Personalized Approaches of Medicine: Advances in genetic research and finding biomarkers create an opportunity toward more tailored glaucoma therapies, based on a patient's genetic profile. This will offer more effective treatments, reduced side effects, and improved outcomes because treatment will be optimized for specific patient needs.
- Combination Therapies for Multi-Drug Resistance: Given that a patient may not respond to one treatment, combination therapies offer the possibility of targeting several mechanisms of the disease. Innovative multi-drug solutions that target different aspects of the disease can dramatically enhance treatment outcome and increase the market share of combination therapies in the glaucoma space.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Glaucoma Medication Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Glaucoma Medication Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Merck and Co., Inc. Novartis Allergan AERIE PHARMACEUTICALS, INC. Bausch and Lomb Incorporated Pfizer Santen Pharmaceutical. Source: glaucoma-medication-market
The market is expected to grow at a CAGR of 10.2%
Asia Pacific region dominated the Glaucoma Medication Market in 2023
North America region dominated the Glaucoma Medication Market in 2023
The Glaucoma Medication Market is estimated to witness a CAGR of 3.5% from 2023 to 2031
Asia Pacific is estimated to grow at the highest CAGR over the forecast year (2023: 2031)
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Glaucoma Medication Market - By Drug Class
1.3.2 Glaucoma Medication Market - By Disease
1.3.3 Glaucoma Medication Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GLAUCOMA MEDICATION MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. GLAUCOMA MEDICATION MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GLAUCOMA MEDICATION MARKET - GLOBAL MARKET ANALYSIS
6.1. GLAUCOMA MEDICATION - GLOBAL MARKET OVERVIEW
6.2. GLAUCOMA MEDICATION - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. GLAUCOMA MEDICATION MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. BETA BLOCKER
7.3.1. Overview
7.3.2. Beta Blocker Market Forecast and Analysis
7.4. PROSTAGLANDIN ANALOG
7.4.1. Overview
7.4.2. Prostaglandin Analog Market Forecast and Analysis
7.5. CARBONIC ANHYDRASE INHIBITOR
7.5.1. Overview
7.5.2. Carbonic Anhydrase Inhibitor Market Forecast and Analysis
7.6. ALPHA ADRENERGIC AGONISTS
7.6.1. Overview
7.6.2. Alpha Adrenergic Agonists Market Forecast and Analysis
7.7. COMBINATION DRUGS
7.7.1. Overview
7.7.2. Combination Drugs Market Forecast and Analysis
8. GLAUCOMA MEDICATION MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE
8.1. OVERVIEW
8.2. DISEASE MARKET FORECASTS AND ANALYSIS
8.3. CLOSE ANGLE GLAUCOMA
8.3.1. Overview
8.3.2. Close Angle Glaucoma Market Forecast and Analysis
8.4. OPEN ANGLE GLAUCOMA
8.4.1. Overview
8.4.2. Open Angle Glaucoma Market Forecast and Analysis
9. GLAUCOMA MEDICATION MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Glaucoma Medication Market Overview
9.1.2 North America Glaucoma Medication Market Forecasts and Analysis
9.1.3 North America Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.1.4 North America Glaucoma Medication Market Forecasts and Analysis - By Disease
9.1.5 North America Glaucoma Medication Market Forecasts and Analysis - By Countries
9.1.5.1 United States Glaucoma Medication Market
9.1.5.1.1 United States Glaucoma Medication Market by Drug Class
9.1.5.1.2 United States Glaucoma Medication Market by Disease
9.1.5.2 Canada Glaucoma Medication Market
9.1.5.2.1 Canada Glaucoma Medication Market by Drug Class
9.1.5.2.2 Canada Glaucoma Medication Market by Disease
9.1.5.3 Mexico Glaucoma Medication Market
9.1.5.3.1 Mexico Glaucoma Medication Market by Drug Class
9.1.5.3.2 Mexico Glaucoma Medication Market by Disease
9.2. EUROPE
9.2.1 Europe Glaucoma Medication Market Overview
9.2.2 Europe Glaucoma Medication Market Forecasts and Analysis
9.2.3 Europe Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Glaucoma Medication Market Forecasts and Analysis - By Disease
9.2.5 Europe Glaucoma Medication Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Glaucoma Medication Market
9.2.5.1.1 Germany Glaucoma Medication Market by Drug Class
9.2.5.1.2 Germany Glaucoma Medication Market by Disease
9.2.5.2 France Glaucoma Medication Market
9.2.5.2.1 France Glaucoma Medication Market by Drug Class
9.2.5.2.2 France Glaucoma Medication Market by Disease
9.2.5.3 Italy Glaucoma Medication Market
9.2.5.3.1 Italy Glaucoma Medication Market by Drug Class
9.2.5.3.2 Italy Glaucoma Medication Market by Disease
9.2.5.4 Spain Glaucoma Medication Market
9.2.5.4.1 Spain Glaucoma Medication Market by Drug Class
9.2.5.4.2 Spain Glaucoma Medication Market by Disease
9.2.5.5 United Kingdom Glaucoma Medication Market
9.2.5.5.1 United Kingdom Glaucoma Medication Market by Drug Class
9.2.5.5.2 United Kingdom Glaucoma Medication Market by Disease
9.2.5.6 Rest of Europe Glaucoma Medication Market
9.2.5.6.1 Rest of Europe Glaucoma Medication Market by Drug Class
9.2.5.6.2 Rest of Europe Glaucoma Medication Market by Disease
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Glaucoma Medication Market Overview
9.3.2 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis
9.3.3 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis - By Disease
9.3.5 Asia-Pacific Glaucoma Medication Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Glaucoma Medication Market
9.3.5.1.1 Australia Glaucoma Medication Market by Drug Class
9.3.5.1.2 Australia Glaucoma Medication Market by Disease
9.3.5.2 China Glaucoma Medication Market
9.3.5.2.1 China Glaucoma Medication Market by Drug Class
9.3.5.2.2 China Glaucoma Medication Market by Disease
9.3.5.3 India Glaucoma Medication Market
9.3.5.3.1 India Glaucoma Medication Market by Drug Class
9.3.5.3.2 India Glaucoma Medication Market by Disease
9.3.5.4 Japan Glaucoma Medication Market
9.3.5.4.1 Japan Glaucoma Medication Market by Drug Class
9.3.5.4.2 Japan Glaucoma Medication Market by Disease
9.3.5.5 South Korea Glaucoma Medication Market
9.3.5.5.1 South Korea Glaucoma Medication Market by Drug Class
9.3.5.5.2 South Korea Glaucoma Medication Market by Disease
9.3.5.6 Rest of Asia-Pacific Glaucoma Medication Market
9.3.5.6.1 Rest of Asia-Pacific Glaucoma Medication Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Glaucoma Medication Market by Disease
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Glaucoma Medication Market Overview
9.4.2 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis
9.4.3 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis - By Disease
9.4.5 Middle East and Africa Glaucoma Medication Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Glaucoma Medication Market
9.4.5.1.1 South Africa Glaucoma Medication Market by Drug Class
9.4.5.1.2 South Africa Glaucoma Medication Market by Disease
9.4.5.2 Saudi Arabia Glaucoma Medication Market
9.4.5.2.1 Saudi Arabia Glaucoma Medication Market by Drug Class
9.4.5.2.2 Saudi Arabia Glaucoma Medication Market by Disease
9.4.5.3 U.A.E Glaucoma Medication Market
9.4.5.3.1 U.A.E Glaucoma Medication Market by Drug Class
9.4.5.3.2 U.A.E Glaucoma Medication Market by Disease
9.4.5.4 Rest of Middle East and Africa Glaucoma Medication Market
9.4.5.4.1 Rest of Middle East and Africa Glaucoma Medication Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Glaucoma Medication Market by Disease
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Glaucoma Medication Market Overview
9.5.2 South and Central America Glaucoma Medication Market Forecasts and Analysis
9.5.3 South and Central America Glaucoma Medication Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Glaucoma Medication Market Forecasts and Analysis - By Disease
9.5.5 South and Central America Glaucoma Medication Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Glaucoma Medication Market
9.5.5.1.1 Brazil Glaucoma Medication Market by Drug Class
9.5.5.1.2 Brazil Glaucoma Medication Market by Disease
9.5.5.2 Rest of South and Central America Glaucoma Medication Market
9.5.5.2.1 Rest of South and Central America Glaucoma Medication Market by Drug Class
9.5.5.2.2 Rest of South and Central America Glaucoma Medication Market by Disease
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. GLAUCOMA MEDICATION MARKET, KEY COMPANY PROFILES
11.1. MERCK AND CO., INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NOVARTIS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ALLERGAN
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. AERIE PHARMACEUTICALS, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BAUSCH AND LOMB INCORPORATED
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. SANTEN PHARMACEUTICAL.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1.Merck and Co., Inc.
2.Novartis
3.Allergan
4.AERIE PHARMACEUTICALS, INC.
5.Bausch and Lomb Incorporated
6.Pfizer
7.Santen Pharmaceutical.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For